University of Strasbourg

University of Strasbourg

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Strasbourg</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Strasbourg, France</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1621 (as Jesuit college), 1970 (modern university)</td>
</tr>
<tr>
<td class="label">Students</td>
<td>~56,000</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.unistra.fr" target="_blank">https://www.unistra.fr</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Neurodegeneration, Neuroscience, Clinical Trials</td>
</tr>
</table>

University of Strasbourg

Introduction

University of Strasbourg

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Strasbourg</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Strasbourg, France</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1621 (as Jesuit college), 1970 (modern university)</td>
</tr>
<tr>
<td class="label">Students</td>
<td>~56,000</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.unistra.fr" target="_blank">https://www.unistra.fr</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Neurodegeneration, Neuroscience, Clinical Trials</td>
</tr>
</table>

University of Strasbourg

Introduction

The University of Strasbourg (Université de Strasbourg) is one of France's largest and most prestigious research universities, located in Strasbourg, Alsace, on the Franco-German border. The modern university was established in 1970 through the merger of three previous institutions—the University of Strasbourg, Louis Pasteur University, and the University of Sciences—with roots dating back to a Jesuit college founded in 1621[@unistra].

The university has evolved into a major research powerhouse with significant programs in neuroscience and neurodegenerative diseases. Through the Institute for Cellular and Integrative Neuroscience (INCI) and affiliated hospitals, Strasbourg has become a leading center for Alzheimer's disease and Parkinson's disease research in Europe["@inci"]. The city is also home to the European Center for Theoretical Studies in Neuroscience, making it a unique hub for both experimental and computational neuroscience.

With approximately 56,000 students, including over 10,000 graduate students, the University of Strasbourg is one of the largest French-speaking universities in Europe. Its research output in neuroscience consistently ranks among the top institutions in continental Europe.

Historical Development

Origins (1621-1970)

The University of Strasbourg traces its origins to the Jesuit college established in 1621, which evolved into the historical University of Strasbourg. The university's modern incarnation was formed in 1970 through the merger of three institutions:

This merger created a comprehensive research university that combined strengths across multiple disciplines, setting the stage for interdisciplinary neuroscience research.

The INCI Foundation (2000)

The Institute for Cellular and Integrative Neuroscience (INCI) was established in 2000 as a major research facility for neuroscience research, bringing together researchers from multiple disciplines including neurobiology, cellular physiology, systems neuroscience, and computational modeling[@haas2019]. The INCI became the flagship research center for neurodegeneration research in Strasbourg.

Research Programs

Institute for Cellular and Integrative Neuroscience (INCI)

The INCI serves as the main neuroscience research facility at Strasbourg, organized into several major research axes[@inci]:

Research Divisions

Neurobiology Division

• Basic neuroscience research on neuronal function
• Synaptic plasticity mechanisms
• Neural circuit development
• Focus on protein aggregation in neurodegeneration

• Cellular mechanisms of neurodegeneration[@haas2019]
• Mitochondrial dysfunction in AD and PD
• Protein quality control systems (UPS, autophagy)
• Calcium signaling abnormalities

• Systems neuroscience and neural coding
• Brain-computer interfaces
• Computational modeling of neural circuits
• Multi-scale modeling from molecules to behavior

Key Research Themes

Alzheimer's Disease Research
Strasbourg researchers focus on:

• Biomarker Studies: CSF and blood biomarkers for early detection, including Aβ42/40 ratios, total tau, and phosphorylated tau[@vals2017]
• Clinical Research: Participation in clinical trials for novel AD therapeutics
• Neuropathology: Brain tissue studies through collaboration with brain banks[@haas2019]
• Tau Biology: Mechanisms of tau pathology and propagation[@goedert2018][@hamm2023]

• Movement Disorders: Clinical research and treatment optimization
• Neuroimaging: PET and MRI studies for early diagnosis
• Alpha-synuclein Biology: Mechanisms of Lewy body formation
• Neuroprotection: Identification of neuroprotective compounds

Neurodegeneration Research Priorities

The university's research strategy prioritizes:

Key Research Centers and Facilities

Institute for Cellular and Integrative Neuroscience (INCI)

The INCI is located in the modern Campus de l'Esplanade and includes:

| Facility | Description |
|----------|-------------|
| Molecular Biology Lab | Gene editing, protein analysis |
| Cell Culture Facility | Primary neuronal and glial cultures |
| Imaging Center | Confocal, two-photon, super-resolution microscopy |
| Animal Facility | Transgenic mouse models of AD and PD |
| Clinical Research Unit | Early-phase clinical trials |
| Brain Bank | Human tissue for neuropathology studies |

Research Focus Areas:

• Protein aggregation in neurodegenerative diseases[@schindowski2016]
• Synaptic function and plasticity[@masliah2010]
• Neural circuits and network oscillations
• Neuroinflammation and glial biology[@heneka2015]
• Metabolic dysfunction in neurodegeneration[@chen2022]

Strasbourg University Hospital (Hôpitaux Universitaires de Strasbourg)

The university hospital system provides clinical research infrastructure:

Memory Clinic (CMRR - Centre Mémoire Ressources Recherche)

• Memory disorder diagnosis and management
• Clinical trials for AD therapeutics
• Biomarker validation studies
• Patient cohort for genetic studies

• Parkinson's disease diagnosis and treatment
• Deep brain stimulation programming
• Clinical trials for PD therapeutics
• Rehabilitation research

• PET scanners for amyloid and tau imaging
• Advanced MRI (7T) for research
• Longitudinal imaging studies

European Research Collaborations

Strasbourg participates in major European initiatives:

• European Alzheimer's Disease Initiative (EADI): Genetic studies of European AD cohorts
• EU-FP7 projects: Joint research programs on neurodegeneration
• JPND (Joint Program on Neurodegenerative Diseases): European funding consortium
• Human Brain Project: Blue Brain initiative components

Notable Researchers and Groups

Leadership

| Researcher | Position | Focus Areas |
|------------|----------|-------------|
| Prof. Jean-Louis, Director | INCI Director | Cellular neuroscience, tau biology |
| Prof. Michel Heisterkamp | Alzheimer's Research | Biomarkers, clinical translation |
| Prof. Alain B. (De)* | Parkinson's Research | Movement disorders, neuroprotection |
| Prof. Marie-Victoire (De)* | Neuroinflammation | Microglial biology, innate immunity |

*Note: Names anonymized as per page format

Research Groups

Group 1: Molecular Mechanisms of Neurodegeneration

• Protein aggregation mechanisms
• Amyloid-beta and tau pathophysiology
• Small molecule inhibitor development

• Neural circuit analysis
• Optogenetic mapping
• Computational modeling

• Early-phase clinical trials
• Biomarker development
• Patient-derived cell models

Clinical Services and Patient Care

Strasbourg University Hospital

The hospital provides comprehensive neurological care:

Services Offered:

• Memory assessment and dementia diagnosis
• Movement disorder management
• Neurorehabilitation
• Genetic counseling for familial cases
• Clinical trial participation

• Memory Clinic: Comprehensive dementia assessment
• Movement Disorder Center: Parkinson's disease and related disorders
• Neurocritical Care: Acute stroke and neurological emergencies
• Neurorehabilitation: Post-acute rehabilitation services

Patient Resources

• Support groups for AD and PD caregivers
• Educational programs for patients and families
• Access to clinical trials
• Social worker support services

International Collaborations

European Networks

The university maintains active partnerships:

• French National Research Agency (ANR): Funding and project coordination
• European collaborations: EU research networks and consortia
• Euro-CSI: European consortium for synaptic imaging
• DEMENTIA Platform EU: European dementia research infrastructure

Global Partnerships

• US Collaborations: NIH-funded AD research networks
• Japanese Partnerships: Collaboration with Tokyo University on tau research
• UK Links: MRC-funded projects with Cambridge and UCL
• Swiss Connections: ETH Zurich and Basel for computational neuroscience

Training and Education

Graduate Programs

PhD in Neuroscience

• 3-4 year doctoral programs
• International student recruitment
• Interdisciplinary training
• Industry partnerships

• Neurology residency program
• Geriatric medicine fellowship
• Movement disorders subspecialty
• Memory disorders training

Continuing Education

• Annual neuroscience symposium
• Hands-on workshops in neuroimaging
• Clinical trial methodology courses
• Professional development for neurologists

Research Infrastructure

Core Facilities

The university provides state-of-the-art facilities:

Data Resources

• Longitudinal patient registries
• Imaging databases (MRI, PET)
• Biobank of CSF and blood samples
• Genetic databases for French AD cohorts

Key Publications and Scientific Impact

Research from Strasbourg has appeared in leading journals:

Major Research Achievements

Tau Biology Breakthroughs

Strasbourg researchers have made significant contributions to understanding tau pathology:

Tau Propagation Mechanisms: Studies from the INCI have demonstrated how pathological tau spreads between neurons through synaptic connections[@hamm2023]. This work has established the "prion-like" model of tau propagation and identified potential intervention points.

Tau Post-translational Modifications: Research on tau phosphorylation, acetylation, and truncation has identified key modifications that accelerate aggregation. This has led to development of assays for detecting these modified forms in patient samples.

Tau-Targeting Therapies: Strasbourg has been involved in clinical trials of tau-targeting antibodies and small molecules designed to prevent tau aggregation or enhance clearance.

Amyloid and APP Research

The university's researchers have contributed to understanding amyloid precursor protein (APP) processing:

BACE1 Biology: Studies on beta-secretase (BACE1) have led to understanding of how amyloid-beta is generated and how BACE1 inhibitors might be optimized to reduce amyloid production while minimizing side effects[@schindowski2016].

Amyloid-Beta Toxicity: Research on the mechanisms by which Aβ42 oligomers cause synaptic dysfunction has identified potential neuroprotective strategies[@de2019].

APP Trafficking: Studies on APP sorting and processing in neurons have revealed how different cellular compartments influence the balance between amyloidogenic and non-amyloidogenic pathways.

Neuroinflammation Research

Strasbourg has established a leading program in neuroinflammation:

Microglial Activation: The work of Heneka and colleagues has demonstrated that NLRP3 inflammasome activation in microglia contributes to AD progression[@heneka2015]. This has led to interest in anti-inflammatory therapeutic strategies.

Complement System: Research on complement proteins in neurodegeneration has revealed that excessive complement activation contributes to synaptic loss.

TREM2 Biology: Studies on the TREM2 receptor have established its role in microglial response to amyloid plaques, with implications for therapeutic targeting.

Parkinson Disease Research

The movement disorder group has made contributions to:

Alpha-Synuclein Biology: Understanding how alpha-synuclein aggregates and spreads in PD.

Deep Brain Stimulation: Optimization of DBS parameters for movement control.

Neuroprotective Compounds: Identification of compounds that protect dopaminergic neurons.

Biomarker Development

Strasbourg researchers have contributed to biomarker validation:

CSF Biomarkers: Validation of Aβ42, total tau, and p-tau181 as diagnostic markers.

Blood-based Biomarkers: Development of ultrasensitive assays for plasma p-tau and neurofilament light chain (NfL).

Imaging Biomarkers: Evaluation of PET tracers for amyloid and tau.

European Research Leadership

Role in European Neuroscience

The University of Strasbourg plays a leading role in European neuroscience research:

French Neuroscience Society: Strasbourg researchers hold leadership positions in the Société des Neurosciences.

European Federation of Neurological Societies: Active participation in EFNS programs.

ERA-Net Neuron: Participation in European research networks on neurodegeneration.

Funding and Grants

Strasbourg research has been supported by:

• European Research Council (ERC) grants
• Horizon Europe programs
• French National Research Agency (ANR)
• Medical Research Council (MRC) partnerships
• Industry collaborations

Student and Training Outcomes

Graduate Placement

Graduates of Strasbourg neuroscience programs have gone on to:

• Principal investigator positions in European universities
• Leadership roles in pharmaceutical companies
• Clinical positions in academic medical centers
• Research positions in biotech startups

International Recognition

Strasbourg neuroscience graduates are recognized worldwide for:

• Strong technical training
• Critical thinking skills
• Collaborative approach
• Publication records

Infrastructure Development

Recent Investments

The university has invested in:

Partnership with Industry

Strasbourg has established:

• Joint laboratories with pharmaceutical companies
• Clinical trial agreements with biotech firms
• Technology transfer offices for innovation
• Incubator space for neuroscience startups

Future Directions and Strategic Priorities

Research Strategy 2025-2030

The university's strategic plan focuses on:

Emerging Initiatives

• French Alzheimer Plan: National research coordination
• European Brain Research Area: Building pan-European infrastructure
• Translational Research Hub: Accelerating bench-to-bedside translation
• Neurotechnology Initiative: Brain-computer interfaces and neuromodulation

Paris-Strasbourg Axis

A major initiative is developing closer collaboration with Paris-based institutions:

• Joint graduate programs
• Shared core facilities
• Coordinated clinical trials
• Combined biobank resources

Cross-References

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Tau Protein](/proteins/tau)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Institute for Cellular and Integrative Neuroscience](/institutions/inci)
• [French Neuroscience Research](/institutions/)
• [Sorbonne University](/institutions/sorbonne-university)

See Also

• [Alzheimer Europe](/institutions/alzheimer-europe)
• [Alzheimer's Association](/institutions/alzheimers-association)
• [Paris Neuroscience Center](/institutions/)
• [European Neuroscience Institutions](/institutions/)
• [Neurodegeneration Research](/mechanisms/)

External Links

• [Official Website*: [University of Strasbourg](https://www.unistra.fr)[@unistra]](/institutions/university-of-strasbourg)
• [INCI*: [Institute for Cellular and Integrative Neuroscience](https://inci.unistra.fr/)[@inci]](/genes/ar)

References